In resource-limited settings, mortality in the initial months following antiretroviral therapy (ART) initiation remains unacceptably high. Novel tools to identify patients at highest risk of poor outcomes are needed. We evaluated whether elevated C-reactive protein (CRP) concentrations predict poor outcomes among people living with HIV (PLWH) initiating ART.
We enrolled and followed for 3-months consecutive PLWH with pre-ART CD4+ T-cell counts 350 cells/μl or less initiating ART from two HIV clinics in Uganda. Pre-ART CRP concentrations were measured from capillary blood using a point-of-care (POC) assay. After excluding patients with prevalent tuberculosis – the leading cause of HIV death – we measured 3-month mortality rates using Kaplan–Meier curves, used Cox regression to compare differences in survival, and used logistic regression to compare differences in the odds of opportunistic infections, between patients with and without elevated POC CRP (≥8 mg/l).
Of 1293 patients included [median CD4+ T-cell count 181 (interquartile range 82–278)], 23 (1.8%) died within 3 months, including 19 of 355 (5.4%) with elevated POC CRP and four of 938 (0.4%) with nonelevated POC CRP. Eighty-six (6.7%) patients were diagnosed with opportunistic infections, including 39 of 355 (11.0%) with elevated POC CRP and 47 of 938 (5.0%) with nonelevated POC CRP. Elevated POC CRP was associated with mortality (adjusted hazard ratio 10.87, 95% confidence interval 3.64–32.47) and opportunistic infection (adjusted odds ratio 1.95, 95% confidence interval 1.23–3.07).
Among PLWH with advanced HIV, elevated pre-ART POC CRP concentrations are associated with early mortality and opportunistic infections. Pre-ART POC CRP testing may reduce mortality by identifying patients at high risk for poor outcomes.
aDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
bDepartment of Medicine, Makerere University College of Health Sciences
cMakerere University-UCSF Research Collaboration
dMakerere University Joint AIDS Program, Kampala, Uganda
eDivision of HIV, Infectious Diseases and Global Medicine
fDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Correspondence to Christina Yoon, MD, MPH, MAS, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Ave., Room 5K1, San Francisco, CA 94110, USA. Tel: +00 1 415 206 3514; e-mail: Christina.firstname.lastname@example.org
Received 10 September, 2018
Revised 30 November, 2018
Accepted 10 December, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).